Global WholeHealth Partners announced it developed a diagnostic test to identify dementia using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis.
"This could simply be described as nothing short of a Medical Breakthrough in Dementia Diagnostic Testing,” said Charles Strongo, CEO of Global WholeHealth Partners, Corp. “Nunzia Pharmaceutical with nutraceutical for anxiety and stress based on their patented formula and their pharmaceutical drug they are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests.”
Nutritional deficiencies: Not drinking enough liquids (dehydration); not getting enough thiamin (vitamin B-1), which is common in people with chronic alcoholism; and not getting enough vitamins B-6 and B-12 in your diet can cause dementia-like symptoms. Copper and vitamin E deficiencies also can cause dementia symptoms.
“Early detection for Dementia disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures,” commented Strongo. "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests."
